Evan J. Lipson, MD

Johns Hopkins University School of Medicine

Dr. Lipson is Professor of Oncology at the Johns Hopkins University School of Medicine and he serves as an advisor on HBI-8000. He completed his internship and residency in internal medicine at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson specializes in skin cancer and cancer immunotherapy, with a focus on evaluating novel therapies for patients with high-risk or advanced disease. His research has included pioneering work on the use of immune checkpoint inhibitors in organ transplant recipients with advanced cancer and on LAG-3 immune checkpoint therapy, including pivotal clinical trials that contributed to FDA approval of a treatment for advanced melanoma. He is also an educator in cancer immunotherapy, with a particular focus on the management of immune-mediated toxicities associated with novel cancer therapies.